References
- Ruiz-Argüelles GJ, Gómez-Almaguer D. Lessons learned treating patients with multiple myeloma in resource-constrained settings. Curr Hematol Malig Rep. 2021;16(1):40–44. Epub 2021 Mar 11. PMID: 33704651.
- Kyle RA. Long-term survival in multiple myeloma. N Engl J Med. 1983;308(6):314–316.
- Kyle RA. Multiple myeloma: review of 896 cases. Mayo Clin Proc. 1975;50:29–40.
- Myeloma cancer stat facts [Internet]. SEER. 2021. [cited 2021 Sep 10]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html.
- Myeloma survival statistics [Internet]. Cancer Research UK. 2017. [cited 2021 Sep 10]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/survival#heading-Zero.
- Hungria VT, Maiolino A, Martinez G, et al. Observational study of multiple myeloma in Latin America. Ann Hematol. 2017;96(1):65–72.
- Murrieta-Álvarez I, Steensma DP, Olivares-Gazca JC, et al. Treatment of persons with multiple myeloma in underprivileged circumstances: real-world data from a single institution. Acta Haematol. 2020;143(6):552–558.
- Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37(S1):62–65.
- López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant. 2009;44(11):715–719.
- Schemper M, Smith TL. A note on quantifying follow up in studies of failure time. Control Clin Trial. 1996;17(4):343–346.
- Hemminki K, Först A, Hansson M. Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016. Sci Rep. 2021;11:17272.
- Ruiz-Argüelles GJ, Gómez-Rangel JD, Ruiz-Delgado GJ, et al. Multiple myeloma in Mexico: a 20-year experience at a single institution. Arch Med Res. 2004;35(2):163–167.
- Ruiz-Argüelles GJ, Gómez-Almaguer D. Perspectives in diagnosis and therapeutics in hematology. Rev Invest Clin Mex. 2021;73:306–309.
- Gale RP. Treating plasma cell myeloma in developing countries: does everyone need the newest drugs? Acta Haematol. 2020;143(6):513–515.
- Colunga-Pedraza PR, Gomez-Cruz GB, Colunga-Pedraza JE, et al. Geographic hematology: some observations in Mexico. Acta Haematol. 2018;140(2):114–120.:
- Kumar S, Jacobus S, Cohen A, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317–1330.
- Ludwig H, Novis-Durie S, Meckl A, et al. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020;25(9):1406–1413.
- Kumar S, Berdeja J, Niesvizky R, et al. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019;33(7):1736–1746.:
- Binder M, Nandakumar B, Rajkumar S, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2021. DOI: https://doi.org/10.1038/s41375-021-01453-5.